What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force

P S Aisen, E Siemers, D Michelson, S Salloway, C Sampaio, M C Carrillo, R Sperling, R Doody, P Scheltens, R Bateman, M Weiner, B Vellas

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Although the results were disappointing from two recent clinical trials of amyloid-targeting drugs in mild-to-moderate AD, the trials provided information that will be important for future studies, according to the EU-US CTAD Task Force, which met in November 2017 to discuss the EXPEDITION3 and EPOCH trials. These trials tested two of the predominant drug development strategies for AD: amyloid immunotherapy and BACE inhibition in populations largely composed of mild AD dementia patients. The results of these trials support the emerging consensus that effective amyloid-targeted treatment will require intervention in early, even pre-symptomatic stages of the disease. Further, the Task Force suggested that a refinement of the amyloid hypothesis may be needed and that other hypotheses should be more fully explored. In addition, they called for improved biomarkers and other outcome assessments to detect the earliest changes in the development of AD.

Original languageEnglish
Pages (from-to)171-174
Number of pages4
JournalThe Journal of Prevention of Alzheimer’s Disease
Volume5
Issue number3
DOIs
Publication statusPublished - 2018

Cite this

Aisen, P. S., Siemers, E., Michelson, D., Salloway, S., Sampaio, C., Carrillo, M. C., ... Vellas, B. (2018). What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force. The Journal of Prevention of Alzheimer’s Disease, 5(3), 171-174. https://doi.org/10.14283/jpad.2018.23
Aisen, P S ; Siemers, E ; Michelson, D ; Salloway, S ; Sampaio, C ; Carrillo, M C ; Sperling, R ; Doody, R ; Scheltens, P ; Bateman, R ; Weiner, M ; Vellas, B. / What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force. In: The Journal of Prevention of Alzheimer’s Disease. 2018 ; Vol. 5, No. 3. pp. 171-174.
@article{b6aa436cfcbe4763bfe3ca59dc457c63,
title = "What Have We Learned from Expedition III and EPOCH Trials?: Perspective of the CTAD Task Force",
abstract = "Although the results were disappointing from two recent clinical trials of amyloid-targeting drugs in mild-to-moderate AD, the trials provided information that will be important for future studies, according to the EU-US CTAD Task Force, which met in November 2017 to discuss the EXPEDITION3 and EPOCH trials. These trials tested two of the predominant drug development strategies for AD: amyloid immunotherapy and BACE inhibition in populations largely composed of mild AD dementia patients. The results of these trials support the emerging consensus that effective amyloid-targeted treatment will require intervention in early, even pre-symptomatic stages of the disease. Further, the Task Force suggested that a refinement of the amyloid hypothesis may be needed and that other hypotheses should be more fully explored. In addition, they called for improved biomarkers and other outcome assessments to detect the earliest changes in the development of AD.",
author = "Aisen, {P S} and E Siemers and D Michelson and S Salloway and C Sampaio and Carrillo, {M C} and R Sperling and R Doody and P Scheltens and R Bateman and M Weiner and B Vellas",
year = "2018",
doi = "10.14283/jpad.2018.23",
language = "English",
volume = "5",
pages = "171--174",
journal = "The Journal of Prevention of Alzheimer’s Disease",
issn = "2274-5807",
number = "3",

}

Aisen, PS, Siemers, E, Michelson, D, Salloway, S, Sampaio, C, Carrillo, MC, Sperling, R, Doody, R, Scheltens, P, Bateman, R, Weiner, M & Vellas, B 2018, 'What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force' The Journal of Prevention of Alzheimer’s Disease, vol. 5, no. 3, pp. 171-174. https://doi.org/10.14283/jpad.2018.23

What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force. / Aisen, P S; Siemers, E; Michelson, D; Salloway, S; Sampaio, C; Carrillo, M C; Sperling, R; Doody, R; Scheltens, P; Bateman, R; Weiner, M; Vellas, B.

In: The Journal of Prevention of Alzheimer’s Disease, Vol. 5, No. 3, 2018, p. 171-174.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - What Have We Learned from Expedition III and EPOCH Trials?

T2 - Perspective of the CTAD Task Force

AU - Aisen, P S

AU - Siemers, E

AU - Michelson, D

AU - Salloway, S

AU - Sampaio, C

AU - Carrillo, M C

AU - Sperling, R

AU - Doody, R

AU - Scheltens, P

AU - Bateman, R

AU - Weiner, M

AU - Vellas, B

PY - 2018

Y1 - 2018

N2 - Although the results were disappointing from two recent clinical trials of amyloid-targeting drugs in mild-to-moderate AD, the trials provided information that will be important for future studies, according to the EU-US CTAD Task Force, which met in November 2017 to discuss the EXPEDITION3 and EPOCH trials. These trials tested two of the predominant drug development strategies for AD: amyloid immunotherapy and BACE inhibition in populations largely composed of mild AD dementia patients. The results of these trials support the emerging consensus that effective amyloid-targeted treatment will require intervention in early, even pre-symptomatic stages of the disease. Further, the Task Force suggested that a refinement of the amyloid hypothesis may be needed and that other hypotheses should be more fully explored. In addition, they called for improved biomarkers and other outcome assessments to detect the earliest changes in the development of AD.

AB - Although the results were disappointing from two recent clinical trials of amyloid-targeting drugs in mild-to-moderate AD, the trials provided information that will be important for future studies, according to the EU-US CTAD Task Force, which met in November 2017 to discuss the EXPEDITION3 and EPOCH trials. These trials tested two of the predominant drug development strategies for AD: amyloid immunotherapy and BACE inhibition in populations largely composed of mild AD dementia patients. The results of these trials support the emerging consensus that effective amyloid-targeted treatment will require intervention in early, even pre-symptomatic stages of the disease. Further, the Task Force suggested that a refinement of the amyloid hypothesis may be needed and that other hypotheses should be more fully explored. In addition, they called for improved biomarkers and other outcome assessments to detect the earliest changes in the development of AD.

U2 - 10.14283/jpad.2018.23

DO - 10.14283/jpad.2018.23

M3 - Article

VL - 5

SP - 171

EP - 174

JO - The Journal of Prevention of Alzheimer’s Disease

JF - The Journal of Prevention of Alzheimer’s Disease

SN - 2274-5807

IS - 3

ER -